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ABSTRACT 
 
 
 
 
The corneal endothelium is vital in maintaining the functions of the cornea, 
namely hydration, thickness, and transparency. Diseases that impair the corneal 
endothelium are currently remedied solely via surgery. These surgeries present obstacles 
to patients of underserved areas due to cost, ineffectiveness, and lack of access. 
Trachoma, an infection which can cause corneal opacities, is the leading cause of 
infectious blindness in the world. In order to eradicate trachoma, epidemiological data is 
needed. Three villages in Kasigau, Kenya were studied to quantify the occurrence of 
trachoma in the region. The three villages were found to have adequate access to 
antibiotics and an unremarkable incidence of trachoma symptoms. An alternative therapy 
to surgery for corneal endothelial disease is needed. Endothelin-1 (ET-1) has been shown 
to induce cell proliferation in bovine corneal endothelial cells (BCEC). The pathway by 
which this occurs is not well understood. It was hypothesized that ET-1 induces 
proliferation through the mitogen-activated protein kinase (MAPK) pathway. Treatment 
of BCEC with 10 nM ET-1 for 15 min induced a 4.3 fold increase in pERK1/2 (p < 
0.001). Furthermore, 30 min pre-treatment with a MAPK pathway inhibitor before ET-1 
treatment significantly decreased pERK1/2 expression (p<0.05). These results suggest 
that the MAPK pathway may be involved in BCEC ET-1 induced proliferation. 
Keywords: cornea, corneal endothelium, endothelin-1, MAPK, trachoma, keratopathy, 
DSEK, Kenya, ERK 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
The Human Cornea 
The cornea is the transparent tissue that forms the outermost layer of the eye, 
covering the iris, pupil, and anterior chamber. It is avascular but highly innervated by 
nerves. The cornea is essential for visual acuity as it provides 65-75% of the eye’s 
focusing power.
1
 Transparency of the cornea allows light to pass through while non-
transparency (corneal cloudiness) will scatter light and decrease visual acuity. The cornea 
receives oxygen via passive diffusion at the cornea/atmosphere interface and nutrition 
from the tear film as well as the aqueous humor via the pump action of the corneal 
endothelium.
2
  
Structure 
The cornea is comprised of five layers. The most anterior layer is the corneal 
epithelium, made up of stratified squamous epithelial cells. This layer functions as the 
first line of defense for the eye from bacteria and external pathogens and is the site of 
oxygen diffusion. The corneal epithelium lies on a basement membrane known as 
Bowman’s Membrane. This 8-12 μm thick layer is secreted by the epithelial cells and is 
made up of randomly oriented collagen fibrils. Immediately posterior to Bowman’s 
membrane is the corneal stroma which comprises the majority of the cornea. The stroma 
is made up of regularly arranged collagen fibers along with sparsely distributed 
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interconnected keratocytes. The keratocytes function in wound repair and general 
corneal maintenance. Immediately posterior from the stroma lays Descemet’s Membrane 
which is comprised of collagen type IV fibrils, serving as the corneal endothelium’s 
basement membrane. Descemet’s Membrane is acellular, secreted by the corneal 
endothelial cells, and 15-20 μm thick. Recently, a fourth caudal corneal layer, alleged 
anterior to Descemet’s Membrane, was discovered by Dua et al.3 However, much 
controversy has surrounded this so called “Dua’s Layer” as this study has not yet been 
replicated.  
Corneal Endothelium 
 The corneal endothelium forms the fifth caudal layer of the cornea which rises 
from embryonic neural crest cells.
4
 The layer is comprised of a monolayer of simple 
squamous mitochondria-rich cells, hexagonal in shape, that form a barrier between the 
corneal stroma and the aqueous humor in the anterior chamber. The layer is contact 
inhibited in vivo, meaning that its cells will not proliferate naturally. Instead, for wound 
healing purposes, the endothelial cells will either enlarge or migrate to compensate for 
the loss of cells. As the cornea is an avascular organ, it relies on the endothelium for the 
transport of nutrients via pump action across the monolayer. The corneal endothelium 
also regulates the fluid capacity of the cornea.
5
 Fluid from the aqueous humor leaks into 
the stroma in a flux proportional to the integrity of the cell-to-cell tight junctions. Since 
the only method for wound healing is cell enlargement and migration, losing cells in the 
corneal endothelium causes irregular cell-cell connections. Less tight junctions and fewer 
pumps lead to an increase in bulk flow of fluid across the endothelium.
6
 This results in 
stromal swelling (corneal decompensation) and other corneal complications, such as 
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opacification. Therefore, maintaining a proper cell density in the corneal endothelium is 
vital for vision and corneal health. 
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CHAPTER 2 
 
 
CORNEAL ENDOTHELIUM PATHOLOGY 
 
Corneal Endothelial Pathology 
 In young individuals, the corneal endothelium is 4-6 μm thick and comprised of 
about 400,000 cells with a cellular diameter of 20 μm. The corneal endothelial cell 
density decreases gradually with age. At birth, density ranges from 3500-4000 cells/mm
2
. 
Once an individual reaches adulthood, density ranges from 1400-2500 cells/mm
2
. A cell 
density below 400-700 cells/mm
2
 leads to edema and loss of visual acuity.
7
 The leading 
cause of corneal endothelial cell loss is Fuchs’ Endothelial Dystrophy (FED). FED is an 
autosomal dominant trait and is characterized initially by loss of visual acuity in the 
morning. This is due to high fluid content within the cornea that accumulates overnight 
without evaporative potential. This fluid will evaporate as the affected individual exposes 
their cornea to sunlight and air. As the disease worsens and the corneal endothelium 
becomes less dense, more fluid will leak through the corneal endothelium causing corneal 
edema, and vision will be further impaired gradually throughout the day.  
 Another cause for decreased corneal endothelial cell density is surgical error. 
Ultrasonic phacoemulsifiers are often used to degrade lenses in patients’ eyes that present 
clouded or opaque areas called cataracts. Ophthalmologists use these probes in close 
proximity to the corneal endothelium and often inadvertently shear off endothelial cells. 
If a sufficient number of cells are lost, Pseudophakic Bullous Keratopathy will manifest 
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with corneal edema since the corneal endothelium cannot keep the cornea in a healthy 
and relatively dehydrated state, known as deturgescence.
8
  
Trachoma  
 A third cause of corneal insult is trachoma, the result of an infection of Chlamydia 
trachomatis in the eye.
9
 This causes inflammation and scarring in the tarsal conjunctiva 
(eyelid) which, if left untreated, causes the eyelid to invert (entropion) often leading to 
inverted eyelashes that scrape the cornea (trichiasis). Late stage trachoma, called 
trachoma trichiasis, is characterized by entropion, but also corneal opacity. Today, 
trachoma is endemic in 51 countries affecting about 41 million people, mostly women 
and children, who have active trachoma infection and need treatment. It is estimated that 
8.2 million people are blind from Trachoma trichiasis, making it the leading cause of 
infectious blindness worldwide. The bacterium can be spread via direct contact from an 
infected person and also via a fly vector. Therefore, communities and countries with poor 
sanitization practices often show the highest occurrences of trachoma. 
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CHAPTER 3 
 
 
KENYA AND TRACHOMA 
 
WHO & GET 2020 
 The World Health Organization (WHO) leads an international coalition known as 
the Alliance for the Global Elimination of Trachoma by the year 2020 (GET 2020). In 
order to properly eradicate trachoma, GET 2020 coordinates essential activities such as 
epidemiological assessment and mapping of affected regions, project planning, 
implementation, monitoring, disease surveillance, and resource mobilization. It is open to 
all parties - governments, international organizations and nongovernmental organizations 
- who are willing and ready to contribute to international efforts.
10
 
 The “SAFE” strategy was developed by the WHO as a set of methods to help 
fight Trachoma (Figure 3.1). SAFE is an acronym for surgery for trichiasis (inturned 
eyelids), antibiotics, facial cleanliness and environmental improvement.  
These four interventions are necessary for trachoma therapy and prevention and 
have been proven to be effective. In 1998, Pfizer and the Edna McConnell Clark 
Foundation joined the global effort and co-established the International Trachoma 
Initiative (ITI), an independent not-for-profit organization dedicated to the elimination of 
blinding trachoma. Pfizer donates the Zithromax® needed to implement the “A” 
component of the SAFE strategy and reach the goal of elimination. To date, Pfizer has 
donated more than 444 million Zithromax® treatments to people in 21 countries.
11
 Over 
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115 million doses of Zithromax® are approved for shipment in 2015, double that 
of last year’s shipments. 
 
 
Figure 3.1 – SAFE Method The WHO instituded the SAFE method (Surgery, Antiobiotics, Facial cleanliness, 
Environmental change) as a set of methods to help combat trachoma. Source: (Pfizer) 
 
Kenya and Trachoma 
 While the worldwide goal for trachoma eradication is 2020, specific countries 
have their own goals. Kenya has made 2015 as the year in which blinding trachoma 
should be completely eradicated from its country. The International Coalition for 
Trachoma Control estimates that 2.2 million Kenyans live in Trachoma endemic areas, 
with 67 thousand cases of actual blinding trachoma trichiasis.
12
. As of 2010, Zithromax® 
had only been distributed to 3 districts of Kenya (Figure 3.2) 
 
Partners in Caring: Medicine in Kenya 
 Each year a group from Western Kentucky University comprised of pre-
professional students, volunteers, researchers, and medical professionals travels to 
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southern Kenya to offer medical attention to the underserved communities in the Kasigau 
community of the Taita Taveta district (Figure 3.3). A partnership has been built between 
the University and the people of Kasigau that has also incorporated studies including 
topics such as hypertension prevalence
13
, assessment of prenatal outcomes
14
, and human-
wildlife conflict.  In this study, a pilot survey of the occurrence of trachoma was 
conducted on patients in the clinics of three villages in Kasigau (Rukanga, Makwasinyi, 
Bhaguta). This survey was conducted in hopes to help direct efforts for Zithromax 
distribution in Kenya in order to reach the 2015 goal for the elimination of blinding 
trachoma. 
 
 
 
Figure 3.2 – Antibiotic Distribution in Kenya as of 2010 Highlighted regions show districts of Kenya that received 
antibiotics from Pfizer as of the year 2010. Source: (International Coalition for Trachoma Control) 
 
 
9 
 
 
Figure 3.3 - Map of Kenya with a Pin at the Kasigau Region Source: (African Promise, 2014) 
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CHAPTER 4 
 
 
TREATMENT FOR CORNEAL ENDOTHELIAL DYSTROPHY  
 
Treatment for Corneal Endothelial Dystrophy 
 About 40,000 Americans receive a corneal transplant each year. Total corneal 
transplant, known as penetrating keratoplasty (PKP), was initially used to treat corneal 
complications, including trachoma trichiasis. This involved the excision of a patient’s 
cornea and transplantation of a donor graft. The graft is sutured into the patient’s eye with 
ultra-fine sutures which are removed a year post operation.   
In 1998, G. Melles et al. developed Descemet’s Stripping with Endothelial 
Keratoplasty (DSEK) which is now commonly used as the treatment for corneal 
opacities.
15
 This procedure calls for removal of the impaired corneal endothelium along 
with Descemet’s Membrane through an incision in the sclera, followed by transplantation 
of a host corneal endothelium through the same incision. The ocular chamber is then 
pressurized and the patient lies supine for 24 hours to promote adherence of the corneal 
endothelium. DSEK is favored over PKP because it requires minimal restrictions in 
normal activities, provides faster visual recovery, does not require any sutures, and 
causes minimal change in glasses prescription.
16
 
Issues with Surgical Correction of Corneal Opacities 
 
11 
 
Surgical intervention has many risk factors including infection, adverse reaction to 
anesthesia, and physician error. PKP involves complete excision of a whole graft while 
DSEK is less invasive and involves excision of the corneal endothelium only, making 
DSEK the apparent better candidate for surgical correction of corneal complications. 
Studies have been done to gauge the efficacy of DSEK compared to PKP by evaluating 
patient outcomes. Price et al. compared 173 DSEK patients to 410 PKP patients, and 
found that at one year post-transplantation, overall graft success was comparable for 
DSEK and PKP procedures but endothelial cell loss was higher with DSEK.
17
 Similarly, 
Lee et al. found that in terms of surgical risks, complication rates, graft survival (clarity), 
visual acuity, and endothelial cell loss, DSEK appears similar to PKP.
18
 DSEK seems to 
be superior to PKP only in terms of earlier visual recovery, refractive stability, 
postoperative refractive outcomes, wound and suture-related complications (as there are 
none), and intraoperative and late suprachoroidal hemorrhage risk. Therefore, even with 
the discovery of DSEK, outcomes are relatively similar to PKP, making the pressing need 
for alternative solutions to keratopathy still very relevant.  
 Furthermore, access to specialty surgical intervention in rural areas of the United 
States and underdeveloped countries is very poor. Not only are there geographic barriers 
that limit access, such as distance and transportation, but also the high cost of these 
procedures often leaves the impoverished without treatment. Frequently, those in 
developing countries where there are poor sanitization conditions due to lack of water 
and resources are the patients in greatest need of medical attention, yet they are least 
likely to be able to pay for such procedures due to their lack of affluence. Therefore, 
designing a non-surgical and cost effective alternative to corneal transplantation is 
12 
 
desirable in order to help treat those who do not have access to surgery, whether it is for 
geographic or monetary reasons.  
13 
 
CHAPTER 5 
 
 
ENDOTHELIN-1 
 
Endothelin-1 
 Endothelin-1 (ET-1) is a 21 amino acid protein that is found endogenously in the 
human body and has potent vasoconstrictive properties. It is predominantly released by 
vascular endothelial cells to regulate the tone of blood vessels, but it has also been found 
to be secreted by the ciliary epithelium which leaks into the aqueous humor of the eye. 
The aqueous humor is the chamber immediately posterior to the corneal endothelium. As 
the aqueous humor is not vascularized and drained very slowly by the Canal of Schlemm, 
ET-1 is found at concentrations several times higher in the aqueous humor than in blood 
plasma.
19
  
 Endothelin-1 has been shown to promote wound healing via proliferation in the 
bovine corneal endothelium (Figure 5.1).
20
 It was shown that bovine corneal endothelial 
cells treated with 10 nM ET-1 for 72 hours showed significantly faster wound closure 
compared to control.  
14 
 
 
Figure 5.1 – Endothelin-1 Promotes Wound Closure in BCEC. Incubation with 10nM ET-1 for 72h shows enhanced 
wound healing in BCEC cultures.  Error bars are SEM, n = 18 wells from 3 separate experiments. Confluent BCEC 
were mechanically wounded and allowed to heal for 48h in a serum-free medium in the presence or absence of ET-1 or 
5-fluorouracil. ANOVA p < 0.05. (Source: Frazier, L.) 
  
 The intracellular pathway by which corneal cell proliferation occurs after 
treatment with ET-1 is not well understood. Wu et. al showed an increase in corneal 
endothelial proliferation to be linked to an increase in intracellular calcium concentration 
and stimulation of inositol phosphatases.
21,22
 It has also been shown that after ET-1 
treatment there is a significant decrease in the expression of p27, a proliferative inhibitor 
that, unless degraded following phosphorylation, arrests BCECs in a G1 state.
23
 The 
pathway through which these events happen has not been identified. 
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CHAPTER 6 
 
 
MAPK & ERK1/2 
 
MAPK Pathway 
 The mitogen activated protein kinase (MAPK) pathway is activated by mitogenic 
stimuli and is characterized by sequential phosphorylation of cytoplasmic protein kinases. 
The MAPK pathway has been found to play roles in inflammatory responses, 
differentiation, and proliferation among others. The MAPK pathway has also been found 
to lead to a decrease in p27 levels.
24
 Therefore, for the present study, the MAPK pathway 
was selected as a potential candidate for ET-1 induced BCEC proliferation.  
Erk 1/2 
 Extracellular regulated kinase 1 and 2 (Erk 1/2) are related protein-
serine/threonine kinases. Erk 1/2 has been identified as a signal transducer in the MAPK 
pathway and  is readily detectable in mammalian models. The phosphorylation of Erk 1/2 
(pErk 1/2) at the tyrosine and threonine sites is required for enzyme activation.
25
 Erk 1/2 
has been identified as a MAPK playing a role in cell cycle regulation via the 
phosphorylation of p27, which was previously shown to be down regulated in ET-1 
treated BCECs.
26
 Therefore, we hypothesized that Erk ½, as a kinase in the MAPK 
pathway, plays a key role in ET-1 induced BCEC proliferation.  
 In this study, Erk 1/2 and pErk 1/2 are studied via western blot analysis after 
treatment of BCEC with ET-1 and a MAPK inhibitor. Three treatment groups are 
16 
 
established: control cells (untreated), ET-1 treated cells, and ET-1 + PD98059 (MAPK 
pathway inhibitor) treated cells. If ET-1 does indeed stimulate cell proliferation through 
the MAPK pathway, a decrease in ET-1 stimulated phosphorylation of Erk 1/2 will be 
observed after treatment with the MAPK inhibitor. If another pathway were to be 
responsible for the observed proliferation, there should be no change in the ET-1 
stimulation of Erk 1/2 phosphorylation, even after MAPK inhibition.  
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CHAPTER 7 
 
 
MATERIALS AND METHODS 
 
Isolation and Culture of Bovine Corneal Endothelial Cells: 
Bovine eyes were obtained from Kirby and Poe slaughterhouse in Alvaton, KY. 
Excess tissue (muscle, fat and fascia) around the globe were trimmed and the eye was 
then placed cornea side up in a shallow dish lined with sterile gauze. The eyeballs were 
covered with sterile gauze and soaked using 2X antibiotic solution (100X stock 
pen/strep/amphotericin; Invitrogen, Carlsbad, CA) for 30 minutes at room temperature. 
The cornea was then dissected leaving a 1-2 mm sclera rim and transferred to a sterile 
eyecup with the endothelium side up. The endothelium was incubated with Dispase 
(0.025g/mL, Roche) dissolved in EBSS (Earle’s Balanced Salt Solution) for 90 min at 
37°C. After incubation with the Dispase enzyme, endothelial cells were gently scraped 
off into solution using a silicon surgical rubber spatula. Cells were then aspirated with a 
sterile Pasteur pipette and transferred to a 15-mL tube containing 5 mL DMEM 
(Dulbecco’s Modified Eagle Medium). The cells were pelleted by centrifugation at 600xg 
for 2 minutes. The supernatant was discarded and the pellet of cells was re-suspended 
with 5 mL of growth medium. Cells were transferred to T-25 flasks and fed three times 
per week with growth medium (DMEM) supplemented with 10% iron supplemented calf 
serum (HyClone) and 500 μg gentamicin (antibiotic) and 100 μL fungizone (antimycotic) 
for each 100mL of complete growth medium. Cultures were maintained in a CO2 
18 
 
incubator at 37°C and 5% CO2. Trypsin, 0.05% dissolved in calcium free EBSS, 
was used to subculture cells. The second passage cells were used for all experiments. 
Endothelin-1 Stock Preparation 
Endothelin-1 was obtained from Sigma Chemical, St. Louis, MO. The 20 μM ET-
1 stock was prepared in dilute acetic acid. One drop of glacial acetic acid was added to 15 
mL of nano-pure water, 100 μL of the diluted acetic acid was then added to 10 mL of 
nano-pure water and was sterile filtered. 1 mL of dilute acid was added to 50 μg of ET-1 
and 25 μL ET-1 aliquots were prepared and stored at -20°C. 
Antibodies 
P44/42 MAPK (Erk 1/2) (catalog #9102) and phospho-p44/42 MAPK (Erk 1/2) 
(Thr202/Tyr204) (catalog #9101) were purchased from Cell Signaling Technology. The 
source of p44/42 MAPK (Erk 1/2) antibody is rabbit. The source of the Phospho-p44/p42 
MAPK antibody is rabbit and it detects the endogenous levels of p44 and p42 MAP 
kinases when phosphorylated either individually or dually at Thr 202 and Tyr204 of Erk 
1 and Thr185 23 and Tyr187 of Erk  2. It does not cross react with non-phosphorylated 
Erk 1/2.  
ET-1 and MAPK Inhibitor treatment in BCEC 
BCECs were grown to 100% confluence in T-75 flasks and serum starved in 
DMEM for 24 hours to induce quiescence. BCECs were then treated with 10 nM ET-1 
and incubated for 30 minutes. A MAPK pathway inhibitor (PD98059) was used 30 
minutes prior to ET-1 treatment in one flask. Control cells were left untreated in serum-
free DMEM. Protein samples were collected from control, ET-1, and MAPK Inhibitor 
treated cells. 
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Isolation of BCEC Protein 
After appropriate treatment, cells were rinsed twice with cold EBSS for 5 min. 2  
mL of ice cold RIPA buffer (25 mM Tris•HCl, pH 7.6, 150 mM NaCl, 1% NP-40, 1% 
sodium deoxycholate, 0.1% SDS) with protease inhibitor (1:500) and PMSF (1mM) was 
then added to the T-75 flasks. The flasks were then incubated on ice for 5 min. Flasks 
were swirled occasionally on ice during incubation. Using a rubber policeman, cells were 
scraped into a 15-mL conical blue cap tube. To increase yield, the pellet was sonicated 
for 10 seconds with 20% amplitude. Samples were then kept at -20°C for further 
experimentation. 
Estimation of Protein Concentration: 
Protein concentration was determined according to the Peterson modification of 
the Lowry protein determination assay. Samples and BSA standards (10-100 μg) were 
pipetted into cuvettes. Volumes of all samples and standards were brought up to 0.5 mL 
with dH2O. 1 mL of reagent A (equal volumes of copper-tartrate-carbonate solution, 10% 
SDS, 0.8N NaOH and dH2O) was added to all tubes, vortexed immediately, and left for 
10 minutes at room temperature. Following the incubation with reagent A, 0.5 mL of 
reagent B (one part of Folin-Ciocalteu Phenol Reagent to 5 parts of dH2O) was added to 
all tubes and incubated for 25 minutes. Absorbance of standards and samples was read at 
750 nm wavelength. The protein concentration of samples was calculated from the 
standard curve of BSA. 
SDS-PAGE and Western Blotting 
 A 4X sample loading buffer (BioRad) was added in a 1:3 ratio (1 part sample 
buffer: 3 parts sample) to each sample in 1.5-mL centrifuge tube and the mixture was 
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heated for 5 minutes with 2-mercaptoethanol (2%). An equal mass of sample (20 μg) was 
loaded in each well of an Any kD mini protean pre-cast gel (Bio-Rad), and the proteins 
were separated at constant voltage (150 V) for 1 hour. 5 μL of a protein molecular weight 
standard (Bio-Rad) was loaded in two wells of the gel. During electrophoresis, a sheet of 
PVDF was soaked for 30 minutes in methanol. After electrophoresis the gel was washed 
in 15 mL of 1X transfer buffer (30.3 g Tris-base, 144.1 g glycine, water to 1 liter for 
10X) on a shaker at room temperature. The PVDF membrane and filter papers were 
wetted in transfer buffer and a blot sandwich was prepared in the following sequence 
from black side of the cassette to red side of the cassette: filter pad, filter paper, gel, 
PVDF membrane, filter paper and filter pad. Bubbles were removed by rolling a glass rod 
over the sandwich. The gel holder cassette was then closed and placed into the transfer 
tank filled with 1X transfer buffer. Proteins were transferred at a constant 100 V for 2.5 
hours at 4°C. 
 A Pierce Fast Western Blotting kit was used for protein detection and 
quantification. After transfer, the PVDF was removed from the transfer apparatus, split 
into two symmetrical blots, and placed in a clean tray. The blot was incubated with 
primary antibody from Cell Signaling Technology p44/42 MAPK (Erk 1/2) Cat. No. 
9101S and phospho-p44/42 MAPK (Erk 1/2) Cat. No. 9102S for 90 minutes at RT or 
overnight at 4°C. The primary antibodies Erk1/2 and pErk 1/2 were diluted (1:1000) in 
the Fast Western Antibody Diluent, and poured on respective halves of the blot in clean 
trays. The blots were then removed from the primary solution, and placed in clean trays 
with Fast Western Optimized HRP Reagent Secondary Working Dilution for a 15 minute 
incubation. The trays were shaken intermittently during this incubation period. The blots 
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were then removed from the secondary solution, placed in clean incubation trays, and 
washed 3 times with 20 mL of Fast Western 1X Wash Buffer with agitation. After the 
third wash, the blots were placed in a clean tray and 12 mL of the Detection Reagent 
Working Solution was added for a 5 minute incubation period. The blots were then 
removed and dried. Images of fluorescent bands were taken on an Alpha Innotech 
FlourChem HD2 (San Leandro, CA). Densitometry analysis for the bands was done using 
ImageJ.  
 
Trachoma Occurrence Survey Methods 
 Institutional Review Board approval was obtained from Western Kentucky 
University on 12/5/13 (IRB 14-212) (Appendix 1). Three villages of the Kasigau region 
of Kenya, Rukanga, Bhugata, and Makwasinyi, were used as sample populations. Patients 
who arrived to the clinic at which the surveyor was stationed were directed to the 
surveyor. An informed consent document (Appendix 2) was read to each patient detailing 
the purpose of the project, the risks of the project, and the anonymity of the project. After 
the informed consent document, the patient was asked if they desired to continue. If so, 
the investigator gently everted the participant’s upper eyelids by holding up the upper 
eyelid with eyelashes between thumb and forefinger, and bending the eyelid over a 
cotton-tipped applicator. Both upper tarsal regions of each eye were examined for 
symptoms of trachoma. Participant symptoms were compared to a grading card provided 
by the WHO illustrating each stage of trachoma (Figure 7.1). The grade of trachoma was 
noted on a unique specimen form for each participant.  
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Figure 7.1 Trachoma Survey Specimen Form A form proved by the World Health Organization to grade individuals 
participating in an epidemiological survey on the stage of trachoma which the participants present. (Source: WHO) 
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Figure 7.2 WHO Trachoma Grading Card A normal upper tarsal region is shown in conjunction with the five stages 
of trachoma, as developed by the WHO. Infected individuals will initially show minor inflammation, but this will 
progress to scarring and ultimately corneal cloudiness if untreated. (Source: WHO) 
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CHAPTER 8 
 
 
RESULTS 
 
Trachoma occurrence is non-remarkable in Kasigau, Kenya 
 Eighteen participants consented to the trachoma occurrence survey in three 
different villages, 5 from Makwasinyi, 9 from Rukanga, and 4 from Bhugata. Of the 18 
participants, 9 were asymptomatic (Figure 8.1). Three participants showed corneal 
opacities.  
 
Figure 8.1 Trachoma Occurrence Data from 3 Villages in Kasigau, Kenya. Makwasinyi (Mak), Rukanga (Ruk), 
and Bhugata (Bhu), were surveyed for trachoma. Trachomatous inflammation, follicular (TF)—Five or more follicles 
of >0.5 mm on the upper tarsal conjunctiva, Trachomatous inflammation, intense (TI)—Papillary hypertrophy and 
inflammatory thickening of the upper tarsal conjunctiva obscuring more than half the deep tarsal vessels, Trachomatous 
scarring (TS)—Presence of scarring in tarsal conjunctiva, Corneal opacity (CO)—Corneal opacity blurring part of the 
pupil margin, Trachomatous trichiasis (TT)—At least one ingrown eyelash touching the globe, or evidence of epilation 
(eyelash removal). OD-Right Eye, OS- Left Eye.  
Village Mak. Mak. Mak. Mak. Mak. Ruk. Ruk. Ruk. Ruk. Ruk. Ruk. Ruk. Ruk. Ruk. Bhu. Bhu. Bhu. Bhu.
Participant 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
Sex M M F F M F M M M M M F F M F F F F
OD
TS 0 1 0 0 0 0 0 0 0 1 0 0 1 0 0 0 0 0
TI 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 1
TF 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
CO 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0
TT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
OS
TS 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0
TI 0 0 0 0 0 0 1 0 0 0 0 0 0 0 1 0 0 0
TF 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
CO 0 0 0 0 0 0 0 0 0 0 1 0 1 1 0 0 0 0
TT 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
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Endothelin-1 increases phosphorylation of ERK1/2 
 It was hypothesized that ET-1 induced cellular responses involves the MAPK 
pathway by phosphorylation of Erk 1/2. To determine whether ET-1 treated cells exhibit 
enhanced phosphorylation of Erk 1/2, serum-starved cells were treated with 10 nM ET-1 
for 24 hrs. Protein samples were then prepared from untreated and ET-1 treated cells to 
analyze the phosphorylated Erk 1/2 levels through western blotting (Figure 8.2). 
Densitometry analysis revealed that ET-1 induced a significant 5.1-fold increase in 
phosphorylation of ERK compared to control (p < 0.05, n = 3).  
 
Figure 8.2 Endothelin-1 Increases pErk1/2 Expression A: Western blotting results of Control BCEC (A1, A2) and 
10 nM ET-1 treated BCEC (B1, B2).    B: Band densities were measured using the software (Alpha Innotech Imager) 
for Erk 1/2 and pErk 1/2. For each treatment we calculated the relative density of pErk to Erk .  
 
 
 
pErk 1/2 expression is significantly attenuated after treatment with a MAPK 
pathway inhibitor.  
 It was hypothesized that inhibition of the MAPK pathway would lead to 
attenuation of expression in phosphorylated Erk 1/2. Treatment with 10nM PD98059 
A B 
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(Cell Signaling, Cat #9900, MAPK pathway inhibitor drug) led to a decrease by a factor 
of .37 in pErk1/2 expression (Figure 8.3) (p<0.05, n=3).  
 
Figure 8.3 Inhibition of the MAPK Pathway Causes Attenuation of pErk1/2 Expression Western blotting results 
of Control BCEC, 10nM ET-1 treated BCEC, and 10nM PD98059 (MAPK Inhibitor) + 10nM ET-1 treated BCEC.  
 
The ratios of Erk 1/2 expression from ET-1 treated cells and MAPK pathway 
inhibited cells were calculated and plotted for the three different experiments (Figure 
8.4). The same was done for pErk 1/2  expression. pErk 1/2 expression shown as a ratio 
of its expression in MAPK inhibited cells to ET-1 treated cells was significantly lower 
than the ratio calculated for Erk 1/2 expression. (p<0.05, n=3). 
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Figure 8.4 MAPK Pathway Inhibited Cells Express Significantly Less pERK1/2 than ET-1 Treated Cells Extra 
cellular regulated kinase 1 and 2 (ERK) and phosphorylated extra cellular regulated kinase 1 and 2 expression was 
quantified via western blot analysis. The ratios of ERK1/2 and pERK expression in MAPK Pathway inhibited (MAPK-
I) cells and ET-1 treated (ET-1) cells was plotted. Unpaired t-test (p=0.0203). n=3. 
 
 
 Results were then normalized by dividing pErk 1/2 expression by Erk 1/2 
expression (relative densitometry units) in each of the sample treatments (Figure 8.4). 
The MAPK pathway inhibited cells showed a significantly lower ratio of pErk 1/2 / Erk 
1/2 expression compared to ET-1 treated cells. (p<0.05, n=3). 
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Figure 8.5 MAPK Inhibited Cells Express a Significantly Lower Ratio of pErk1/2/Erk1/2 than Control and ET-1 
Treated Cells Levels of Erk1/2 and pErk1/2 expression were quantified via western blotting and analysis by ImageJ 
software. Cells treated with a MAPK Inhibitor (MAPK-I) showed a significantly lower ratio of pErk1/2 to Erk1/2 than 
cells treated with Endothelin-1 (ET-1). Unpaired t-test (p=0.0408). n=3. 
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CHAPTER 9 
 
 
DISCUSSION 
   
Erk 1/2 and the MAPK Pathway are Key Players in ET-1 induced BCEC Events  
 These results suggest that Erk 1/2 plays a key role in ET-1 induced BCEC 
intracellular events as it is seen to be phosphorylated, seen by the significant increase in 
pErk1/2 expression from the western blot. Similarly, the MAPK pathway plays a key 
role, since inhibition of the pathway causes attenuation of phosphorylation of Erk 1/2.  
 These results do not rule out the contribution of another pathway/pathways in ET-
1 stimulation of cell proliferation. Further investigation should be done via proliferative 
assays after treatment with the MAPK inhibitor drug. If the current results and hypothesis 
hold true, a decrease in proliferative activity should be observed at the cell level after 
treatment with an ET-1 and MAPK pathway inhibitor cocktail.  
 
Cause of Corneal Opacities in Trachoma Infected Individuals 
 Trachoma has been traditionally thought to cause corneal opacities via eyelash 
abrasion on the corneal surface after trichiasis. However, many studies have been done 
that show a biological rather than mechanical insult to the cornea. Oh and Tarizzo 
demonstrated that inoculation of rabbit eyes with trachoma in the anterior chamber led to 
diffuse lesion formation in the corneal endothelium (Figure 8.1), which was directly 
related to the rabbit corneal opacities that resulted after trachoma inoculation.
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finding is in agreement with the understanding of the barrier function of the corneal 
endothelium. If lesions (irregular endothelial cell shape and size) in the corneal 
endothelium were to form, barrier function would be compromised and solutes would 
flow into the corneal stroma unimpeded causing corneal opacities, which is indeed what 
the authors observed.   
 
Figure 8.1 Corneal Endothelial Insults after Trachoma Inoculation 3) Corneal endothelium of normal rabbit. 4) 
Endothelial rosettes (arrows). 5-6) Discrete lesion. 7) Diffuse lesions. 8) Higher magnification of 7. All Silver and 
Giemsa Stained Source: (Oh & Tarizzo, 1969).  
 The mechanism by which these corneal endothelial insults occur has also been 
investigated. Shivanna et. al discovered that TNF-α, a proinflammatory cytokine, will 
decrease corneal endothelial barrier function. The authors saw a continual decrease in 
transendothelial electric resistance after TNF-α treatment of BCEC, showing the barrier 
dysfunction. The authors also saw a breakdown of the cytoskeletal proteins cadherin and 
ZO-1 after TNF-α treatment. Interestingly, these reactions were found to be mediated by 
a MAPK protein, p38. The authors were able to inhibit this TNF-α induced barrier 
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dysfunction after treatment with a p38 inhibitor. TNF-α was linked to Trachoma in a 
study done by Conway et. al. The authors found high TNF-α tear fluid levels to be highly 
associated with trachoma infection (p < 0.001) and suggested that TNF-α plays a major 
role in the pathogenesis of scarring trachoma. Other cytokines such as IL-1β, IL-10, IFN-
γ and MMP-9 have also been shown to be closely associated with trachoma as well as 
corneal endothelial apoptosis.
28,29,30
 
 Therefore, it is plausible to hypothesize that corneal opacities in trachoma-
infected individuals occur not only via the mechanical scrapping of eyelashes that results 
from trichiasis, but also via the degradation of the corneal endothelium by 
proinflammatory cytokines such as TNF-α that are  released from the site of infection. As 
the barrier function of the corneal endothelium is indispensable in maintaining corneal 
clarity, this degradation would certainly lead to an increase in water and solute flow into 
the corneal stroma which would lead to the corneal opacities observed in untreated 
individuals with trachoma.  
 
Potential for ET-1 Therapy in Corneal Endothelial Disease 
 As ET-1 has been shown to increase corneal endothelial density, it could be a 
likely candidate for an alternative therapy to surgery. Individuals in early stage trachoma 
infection may be able to take ET-1 treatments preventatively, in order to impede the 
infection from affecting the cornea via cytokine degradation. Similarly, individuals with a 
genetic predisposition for FED may be able to preventatively be treated with ET-1 to 
maintain a proper corneal endothelial density. 
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 The mechanism for treatment of ET-1 is certainly a ripe topic for discussion and 
investigation. As ET-1 promotes cell division and vasoconstriction, specific targeting of 
the drug would be vital, as uncontrolled cell division could lead to cancerous activity. 
Luckily, the corneal endothelium is avascular. Therefore, treatments directly into the 
cornea or anterior chamber would be less hazardous in terms of getting into the 
vasculature than an intravenous treatment. Microinjection of ET-1 into an individual’s 
cornea or anterior chamber may be a plausible route of treatment.  
Small Incidence of Trachoma in Kasigau, Kenya 
 Of the 18 participants surveyed for trachoma in three villages of Kasigau, half 
were showed to be completely asymptomatic, while the other half showed minimal 
symptoms such as small inflammation and follicles. One reason for this may be that the 
participants have proper access to antibiotic treatment. All three villages were found to 
have tetracycline eye drops in stock at their respective medical dispensaries. Tetracycline 
has been shown to treat trachoma effectively. 
31
 Therefore, it is likely that these villages 
are adequately equipped to treat trachoma and similar eye infections. 
 However, the study done was rather limited both in sample size and time spent at 
the sites. The participants were pseudo-selected, as all voluntarily came to the clinic, 
often for other reasons than an eye symptom. House to house paneling would be, and is 
used as, a more effective method for trachoma prevalence surveying. It is important to 
note that the survey done was simply a pilot study, and further surveying and 
epidemiological intervention should be put forth in order to adequately assess this 
region’s need for antibiotic distribution.  
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CHAPTER 10 
 
 
CONCLUSION 
 
 In conclusion, it was found that 10nM ET-1 treatment increases phosphorylation 
of Erk 1/2 in BCEC. This increase in pErk 1/2 expression occurs within the  MAPK 
pathway, as inhibition of the pathway leads to an attenuation of pErk 1/2. As ET-1 
increases BCEC proliferation, it is likely that the MAPK pathway is a key player in the 
reaction after ET-1 treatment. This work represents one more resolved piece of the puzzle 
of designing an alternative therapy to surgery for clouded corneas. These results may help 
to decrease the number of the some 40,000 Americans undergoing costly corneal 
transplantation each year. In the rural United States, and underprivileged countries, 
access to surgery is severely limited. Therefore, these results potentially could be used to 
develop a non-surgical and readily available solution to a compromised cornea.  
 In order to gauge the occurrence of trachoma in Kasigua, Kenya, an 
epidemiological survey was conducted in three villages in the area. Half of the 
participants in the survey showed no symptoms of trachoma whatsoever, while the other 
half displayed minor symptoms. Therefore, the occurrence of Trachoma in the Kasigau 
region of the Taita Taveta district of Kenya, according to this study, is unremarkable. 
This is likely due to the access to antibiotic therapies in the medical dispensaries of each 
village.  
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